polycythemia vera
Infectious disease · 2017–2019
2decisions
2medicines
2carried consumer input
11individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ruxolitinib Treatment of polycythemia vera in patients who are resistant or intolerant to hydroxycarbamide/hydroxyurea. | Nov 2019 | Not recommended | 7 individuals |
| peginterferon alfa-2a Chronic hepatitis B and C infections; also proposed for use in myeloproliferative neoplasms (essential thrombocythemia and polycythemia vera). | Nov 2017 | Recommended with restriction | 4 individuals Rare Cancers Australia |
Who spoke
Rare Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.